• 1
    Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and Hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003;33:12161220.
  • 2
    Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA et al. Omalizumab rapidly decreases nasal allergic responses and FcɛRI on basophils. J Allergy Clin Immunol 2004;113:297302.
  • 3
    Beck LA, Marcotte GV, MacClashan DW, Togias A, Saini S. Omalizumab – induced reduction in mast cell FcRI expression and function. J Allergy Clin Immunol 2004;114:527530.
  • 4
    Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG et al. Omalizumab decreases acute reactions after rush immunotherapy for ragweed-induced allergic rhinitis. J Allergy Clin Immunol 2006;117:134140.
  • 5
    Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalf DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007;119:15501551.
  • 6
    Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007;62:963964.